Molecular Diagnostics Can Help Us Select Optimal Treatment for Men with Metastatic Prostate Cancer.
Androgen receptor positive prostate cancer cells respond much better to abiraterone and enzulatamide.
This suggests that we can select patients using molecular targeting and improve the chances that medications would benefit them.
http://abstracts.asco.org/144/AbstView_144_131581.html
http://abstracts.asco.org/144/AbstView_144_131581.html
If you have any questions, to schedule a consultation or if you need a second opinion, please contact us or call: 646-663-5515